Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Pharmaceutical Technology
JUNE 23, 2025
Robert Barrie June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bayer’s Eylea is a heavyweight of the ophthalmic drug landscape, approved for a range of eye diseases. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.
Let's personalize your content